Drug name: Bevacizumab


Related CSCTT Targets

VEGF [ref.1]P15692

Bevacizumab

Cas.no PubChem ID
216974-75-3 135329020
Known Target
VEGFP15692
Introduction
Bevacizumab, sold under the trade name Avastin, is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer.

Bevacizumab-Structure

...

Reference

  • [1] Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.
    Duda, D. G., et al. (2006). J Clin Oncol 24(9): 1449-1453. [ 16549839 ]
  • [2] Cancer Stem Cells Contribute to Angiogenesis and Lymphangiogenesis in Serous Adenocarcinoma of the Ovary
    Angiogenesis. 2019 Aug;22(3):441-455.. [ 31161471 ]

Back to top